您当前的位置:
N-Formyl-Met-Leu-Phe (Synonyms: fMLP; N-Formyl-MLF)
目录号: PC11189 纯度: ≥98%
CAS No. :59880-97-6
商品编号 规格 价格 会员价 是否有货 数量
PC11189-5mg 5mg ¥588.00 请登录
PC11189-10mg 10mg ¥1058.40 请登录
PC11189-50mg 50mg ¥2234.40 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
N-Formyl-Met-Leu-Phe
中文别名
N-甲酰-L-甲硫氨酰-L-白氨酰-L苯丙氨酸;N-甲酰-L-甲硫氨酰-L-白氨酰-L苯丙氨酸(N-Formyl-Met-Leu-Phe );酪胺盐酸盐;N-甲酰基-Met-Leu-Phe;N-甲酰基-L-蛋氨酰-L-亮氨酰-L-苯丙氨酸
英文名称
N-Formyl-Met-Leu-Phe
英文别名
L-Phenylalanine,N-formyl-L-methionyl-L-leucyl-;N-Formyl-L-methionyl-L-leucyl-L-phenylalanine;N-Formyl-Met-Leu-Phe;fMLF, fMLP;fMLP(N-Formyl-Met-Leu-Phe);For-Met-Leu-Phe-OH;formyl-Met-Leu-Phe;Formyl-Met-Leu-Phe-OH;fMLP;formyl-MLF;N?formyl?L?methionyl?L?leucyl?L?phenylalaninol;N-formyl-L-methyonyl-L-leucyl-L-phenylalanine;N-Formyl-MLF;TYRAMINE HYDROCHLORIDE;Chemotactic peptide;fMLF;fMLP (misnomer but widely used);N-Formyl-Met-Leu-Phe-OH;NSC 350593;F-Met-leu-phe;fMetLeuPhe;N-Formyl-methionyl-leucyl-phenylalanine;N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE;(S)-2-((S)-2-((S)-2-Formamido-4-(methylthio)butanamido)-4-methylpentanamido)-3-phenylpropanoic acid;fMet-Leu-Phe;(2S)-2-[[(2S)-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylprop
Cas No.
59880-97-6
分子式
C21H31N3O5S
分子量
437.55
包装储存

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

生物活性

N-Formyl-Met-Leu-Phe (fMLP; N-Formyl-MLF) is a chemotactic peptide and a specific ligand of N-formyl peptide receptor (FPR). N-Formyl-Met-Leu-Ph is reported to inhibit TNF-alpha secretion.

性状

Solid

IC50 & Target[1][2]

TNF-alpha

体外研究(In Vitro)

Binding of N-Formyl-Met-Leu-Phe to its specific cell surface receptor, N-formyl peptide receptor (FPR), triggers different cascades of biochemical events, eventually leading to cellular activation. FPR is a chemoattractant receptor belonging to the G protein-coupled receptor family. N-Formyl-Met-Leu-Phe promotes osteoblastic commitment and suppresses adipogenic commitment under osteoblastic differentiation conditions. N-Formyl-Met-Leu-Phe stimulates osteogenesis is associated with increased expression of osteogenic markers and mineralization. N-Formyl-Met-Leu-Phe inhibits expression of peroxisome proliferator-activated receptor-γ1. N-Formyl-Met-Leu-Phe-stimulated osteogenic differentiation is mediated via FPR1-phospholipase C/phospholipase D-Ca-calmodulin-dependent kinase II-ERK-CREB signaling pathways. N-Formyl-Met-Leu-Phe, a bacterial-derived peptide, induced proinflammatory cytokine gene expression in human peripheral blood monocytes. Bacterial products LPS and N-Formyl-Met-Leu-Phe synergistically induce inflammatory response via multiple signaling pathways. TLR4, IKKβ-IκBα, and NF-κB signaling pathways are involved in the synergistic induction of TNF-α via p65 nuclear translocation-dependent mechanisms.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

N-Formyl-Met-Leu-Phe promotes bone formation in zebrafish and rabbits. Extensive skeletal development is evident at 5 dpf in over 80% of N-Formyl-Met-Leu-Phe-treated zebrafish. Treatment with N-Formyl-Met-Leu-Phe results in increased expression of Runx2. Bone marrow spaces are widely formed, and connective tissue covering bone is dense, like periosteum, in N-Formyl-Met-Leu-Phe-treated calvaria. N-Formyl-Met-Leu-Phe mediate release of calprotectin from PMN 体外研究. It induces release of calprotectin from PMN in a dose dependent manner. A minimum of 10% of total PMN calprotectin is retained at concentrations of 0.1-10.0 nM of N-Formyl-Met-Leu-Phe.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SequenceShortening

Formyl-MLF

Sequence

Formyl-Met-Leu-Phe

参考文献
溶解度数据
体外研究: 

DMSO : ≥ 82.5 mg/mL (188.55 mM)

H2O : < 0.1 mg/mL (ultrasonic) (insoluble)

* "≥" means soluble, but saturation unknown.

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2855 mL 11.4273 mL 22.8545 mL
5 mM 0.4571 mL 2.2855 mL 4.5709 mL
10 mM 0.2285 mL 1.1427 mL 2.2855 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.75 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.75 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.75 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.75 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2